Douglas Ingram
2018
In 2018, Douglas Ingram earned a total compensation of $1.4M as President and Chief Executive Officer at Sarepta Therapeutics, a 97% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $778,050 |
|---|---|
| Salary | $650,000 |
| Other | $5,822 |
| Total | $1,433,872 |
Ingram received $778.1K in non-equity incentive plan, accounting for 54% of the total pay in 2018.
Ingram also received $650K in salary and $5.8K in other compensation.
Rankings
In 2018, Douglas Ingram's compensation ranked 7,377th out of 14,244 executives tracked by ExecPay. In other words, Ingram earned more than 48.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,377 out of 14,244 | 48th |
Division Manufacturing | 2,862 out of 5,762 | 50th |
Major group Chemicals And Allied Products | 1,078 out of 2,125 | 49th |
Industry group Drugs | 911 out of 1,814 | 50th |
Industry Pharmaceutical Preparations | 714 out of 1,388 | 49th |
Pay ratio
| Douglas Ingram's Pay | $1,433,872 |
|---|---|
| Median Employee's Pay | $329,229 |
| Pay Ratio | 4to 1 |
In 2018, the annual total compensation of Douglas Ingram was $1,433,872.
The annual total compensation of the median employee at Sarepta Therapeutics was $329,229.
The ratio of Douglas Ingram's pay to the pay of median employee was therefore 4 to one.
Source: SEC filing on April 26, 2019.
Ingram's colleagues
We found four more compensation records of executives who worked with Douglas Ingram at Sarepta Therapeutics in 2018.
News
Sarepta Therapeutics CSO Louise Rodino-Klapac's 2021 pay rises 17% to $8.5M
April 25, 2022
Sarepta Therapeutics CSO Louise Rodino-Klapac receives $7.3M in 2020
April 20, 2021
Sarepta Therapeutics CSO Gilmore MMSc's 2019 pay slips 20% to $5.2M
April 21, 2020
Sarepta Therapeutics CSO Gilmore MMSc receives $6.4M in 2018
April 26, 2019